Statins Influence on Cancer Progression??

Statins, widely known for their cholesterol-lowering effects, have garnered attention for their potential pleiotropic effects extending beyond cardiovascular protection. One area of burgeoning interest is the influence of statins on cancer progression. While the primary function of statins is to inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis, their impact on cancer biology is an intriguing facet that warrants deeper exploration.

Statins and Cancer: The Biological Intersection

The potential anti-cancer effects of statins can be attributed to their influence on several biological pathways:

1. Cell Proliferation and Apoptosis: Statins have been shown to induce apoptosis in various cancer cell lines. By inhibiting the mevalonate pathway, statins reduce the production of key intermediates necessary for cell membrane integrity and signaling, thereby inducing programmed cell death and inhibiting cell proliferation. This effect has been observed in breast, prostate, and colorectal cancers, among others.
2. Anti-inflammatory Properties: Chronic inflammation is a known contributor to cancer progression. Statins exhibit anti-inflammatory properties by reducing C-reactive protein (CRP) levels and other inflammatory markers. By mitigating inflammation, statins may help reduce the inflammatory microenvironment that facilitates tumor growth and metastasis.
3. Angiogenesis Inhibition: Tumors require the formation of new blood vessels (angiogenesis) to supply nutrients and oxygen for continued growth. Statins have been reported to inhibit angiogenesis by downregulating vascular endothelial growth factor (VEGF) and other pro-angiogenic factors. This inhibition can starve tumors, limiting their growth and metastatic potential.
4. Immune Modulation: The immune system recognizes and eliminates cancer cells. Statins have been shown to enhance the body's immune response against tumors by modulating the activity of various immune cells, including T-cells and natural killer cells. This immune-enhancing effect may contribute to better cancer surveillance and elimination.
5. Metabolic Reprogramming: Cancer cells often undergo metabolic reprogramming to support rapid growth and proliferation. Statins can disrupt this metabolic flexibility by inhibiting key metabolic pathways, reducing energy production and biosynthesis in cancer cells. This metabolic disruption can impair cancer cell survival and proliferation.

Cardiovascular Prevention in Cancer

• Primary Prevention in Cancer Patients: Statins have been shown to reduce the risk of cardiovascular events in patients without established CVD. This preventive effect is particularly valuable for cancer patients, who are at higher risk due to the cardiotoxic effects of certain chemotherapies.
• Impact on Heart Failure: Statin therapy has been associated with a lower incidence of new-onset heart failure in breast cancer patients receiving anthracycline-based chemotherapy. This suggests that statins may offer cardioprotection during aggressive cancer treatments.
• Overall Survival and Cardiovascular Mortality: Statin use in cancer patients has been linked to improved overall survival and reduced cardiovascular mortality. This dual benefit underscores the importance of statins in managing long-term health in cancer survivors.

Challenges and Considerations

• Drug Interactions: Cancer patients often take multiple medications, which can lead to drug interactions. Statins, particularly when combined with certain chemotherapies, may increase the risk of adverse effects. Careful monitoring and dose adjustments are necessary to mitigate these risks.
• Side Effects: Long-term statin use can cause side effects such as muscle pain, liver enzyme abnormalities, and, rarely, rhabdomyolysis. On statin therapy, monitoring liver function and muscle health is recommended for cancer patients.
• Individualized Treatment: The decision to use statins for cardiovascular prevention in cancer patients should be individualized, taking into account the patient’s cardiovascular risk factors, type of cancer, and overall health status. Clinical judgment is essential to balance the benefits and potential risks.

Thoughts

The pleiotropic effects of statins extend well beyond their cholesterol-lowering capabilities, offering a promising new avenue for cancer research and therapy. Although current evidence suggests potential anti-cancer benefits, more rigorous studies are essential to validate these effects and determine the optimal use of statins in oncology. As we unravel the complexities of cancer biology, integrating statins into cancer treatment protocols could provide new hope for improving patient outcomes and advancing the field of oncology beyond cardiovascular prevention.

References:

McGregor, G., Campbell, A., Fey, S., Tumanov, S., Sumpton, D., Blanco, G., Mackay, G., Nixon, C., Vazquez, A., Sansom, O., & Kamphorst, J. (2020). Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic anti-tumor response.. Cancer research. https://doi.org/10.1158/0008-5472.CAN-19-0644.

Jang, H., Hong, E., Park, S., Byun, H., Koh, D., Choi, M., Kae, S., & Lee, J. (2016). Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation.. Oncology letters, 12 1, 250-256 . https://doi.org/10.3892/OL.2016.4569.

Cantini, L., Pecci, F., Hurkmans, D., Belderbos, R., Lanese, A., Copparoni, C., Aerts, S., Cornelissen, R., Dumoulin, D., Fiordoliva, I., Rinaldi, S., Aerts, J., & Berardi, R. (2020). High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.. European journal of cancer, 144, 41-48 . https://doi.org/10.1016/j.ejca.2020.10.031.

Clendening, J., & Penn, L. (2012). Targeting tumor cell metabolism with statins. Oncogene, 31, 4967-4978. https://doi.org/10.1038/onc.2012.6.

Harshman, L., Wang, X., Nakabayashi, M., Xie, W., Valen?a, L., Werner, L., Yu, Y., Kantoff, A., Sweeney, C., Mucci, L., Pomerantz, M., Lee, G., & Kantoff, P. (2015). Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.. JAMA oncology, 1 4, 495-504 . https://doi.org/10.1001/jamaoncol.2015.0829.

Nayan, M., Punjani, N., Juurlink, D., Finelli, A., Austin, P., Kulkarni, G., Uleryk, E., & Hamilton, R. (2017). Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis.. Cancer treatment reviews, 52, 105-116 . https://doi.org/10.1016/j.ctrv.2016.11.009.

Chang, C., Wu, M., Yang, J., Camarillo, I., & Chang, C. (2015). Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression.. Cancer research, 75 11, 2375-2386 . https://doi.org/10.1158/0008-5472.CAN-14-3076.

Hung, M., Chen, I., Lee, C., Huang, R., Chen, P., Tsai, Y., & Yang, Y. (2017). Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS ONE, 12. https://doi.org/10.1371/journal.pone.0171137.

Ng, K., Ogino, S., Meyerhardt, J., Chan, J., Chan, A., Niedzwiecki, D., Hollis, D., Saltz, L., Mayer, R., Benson, A., Schaefer, P., Whittom, R., Hantel, A., Goldberg, R., Bertagnolli, M., Venook, A., & Fuchs, C. (2011). Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.. Journal of the National Cancer Institute, 103 20, 1540-51 . https://doi.org/10.1093/jnci/djr307.

Lippi, G., & Plebani, M. (2017). Statins for Primary Prevention of Cardiovascular Disease.. Trends in pharmacological sciences, 38 2, 111-112 . https://doi.org/10.1016/j.tips.2016.11.011.

Hindler, K., Cleeland, C., Rivera, E., & Collard, C. (2006). The role of statins in cancer therapy.. The oncologist, 11 3, 306-15 . https://doi.org/10.1634/THEONCOLOGIST.11-3-306.

Gazzerro, P., Proto, M., Gangemi, G., Malfitano, A., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012). Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacological Reviews, 64, 102 - 146. https://doi.org/10.1124/pr.111.004994.

Mills, E., Rachlis, B., Wu, P., Devereaux, P., Arora, P., & Perri, D. (2008). Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.. Journal of the American College of Cardiology, 52 22, 1769-81 . https://doi.org/10.1016/j.jacc.2008.08.039.

Seicean, S., Seicean, A., Plana, J., Budd, G., Marwick, T., & Marwick, T. (2012). Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.. Journal of the American College of Cardiology, 60 23, 2384-90 . https://doi.org/10.1016/j.jacc.2012.07.067.

Kazi, D., Penko, J., & Bibbins-Domingo, K. (2017). Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice.. The Medical clinics of North America, 101 4, 689-699 . https://doi.org/10.1016/j.mcna.2017.03.001.

Boudreau, D., Yu, O., & Johnson, J. (2010). Statin use and cancer risk: a comprehensive review. Expert Opinion on Drug Safety, 9, 603 - 621. https://doi.org/10.1517/14740331003662620.

Thavendiranathan, P., Bagai, A., Brookhart, M., & Choudhry, N. (2006). Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.. Archives of internal medicine, 166 21, 2307-13 . https://doi.org/10.1001/ARCHINTE.166.21.2307.

Reiner, ?. (2013). Statins in the primary prevention of cardiovascular disease. Nature Reviews Cardiology, 10, 453-464. https://doi.org/10.1038/nrcardio.2013.80.